SIK2 inhibitor SIC-19 enhances the sensitivity of PARP inhibitors in triple-negative breast cancers and pancreatic cancers
Oncology Research · 2025
DOI: 10.32604/or.2025.062539 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research, 2025. Verfasst von Qian Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors, Pancreatic Neoplasms, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
- Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, 215009, China.
Zitieren
APA
Li, Q., Zhu, S., Zhu, M., Wang, F., & Zhou, J. (2025). SIK2 inhibitor SIC-19 enhances the sensitivity of PARP inhibitors in triple-negative breast cancers and pancreatic cancers. Oncology Research. https://doi.org/10.32604/or.2025.062539
Vancouver
Li Q, Zhu S, Zhu M, Wang F, Zhou J. SIK2 inhibitor SIC-19 enhances the sensitivity of PARP inhibitors in triple-negative breast cancers and pancreatic cancers. Oncology Research. 2025. doi:10.32604/or.2025.062539
BibTeX
@article{Li2025,
author = {Li, Qian and Zhu, Shunpeng and Zhu, Mingxian and Wang, Fang and Zhou, Jinhua},
title = {SIK2 inhibitor SIC-19 enhances the sensitivity of PARP inhibitors in triple-negative breast cancers and pancreatic cancers},
journal = {Oncology Research},
year = {2025},
doi = {10.32604/or.2025.062539}
}
EUVIMED